Qiagen N.V. $QGEN Shares Bought by Graham Capital Management L.P.

Key Points

• Graham Capital Management L.P. increased its stake in Qiagen N.V. by 92.7% in the first quarter, acquiring an additional 32,774 shares and bringing its total holdings to 68,114 shares valued at approximately $2.735 million.
• Analysts have set a consensus price target of $49.69 for Qiagen, with Barclays issuing an "overweight" rating and a target of $55.00, while Bank of America and UBS have upped their targets to $53.00 and $50.00, respectively.
• Qiagen reported quarterly earnings of $0.60 per share, matching expectations, and a revenue of $533.54 million, exceeding analyst projections of $523.97 million.

Graham Capital Management L.P. lifted its stake in Qiagen N.V. (NYSE:QGEN - Free Report) by 92.7% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 68,114 shares of the company's stock after acquiring an additional 32,774 shares during the quarter. Graham Capital Management L.P.'s holdings in Qiagen were worth $2,735,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Vident Advisory LLC purchased a new stake in shares of Qiagen in the first quarter valued at about $604,000. State of Wyoming boosted its stake in shares of Qiagen by 358.2% in the first quarter. State of Wyoming now owns 12,775 shares of the company's stock valued at $513,000 after purchasing an additional 9,987 shares during the period. Oak Harvest Investment Services purchased a new position in shares of Qiagen in the first quarter valued at $3,188,000. Walleye Trading LLC boosted its stake in Qiagen by 14.6% during the 1st quarter. Walleye Trading LLC now owns 7,367 shares of the company's stock valued at $296,000 after acquiring an additional 936 shares during the last quarter. Finally, SVB Wealth LLC bought a new position in shares of Qiagen in the 1st quarter worth about $31,000. 70.00% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

QGEN has been the subject of several recent analyst reports. Cowen reiterated a "hold" rating on shares of Qiagen in a report on Thursday, August 7th. Wall Street Zen cut Qiagen from a "strong-buy" rating to a "buy" rating in a research note on Monday, August 11th. Barclays assumed coverage on Qiagen in a research report on Tuesday, June 24th. They set an "overweight" rating and a $55.00 price target for the company. Bank of America increased their price objective on Qiagen from $50.00 to $53.00 and gave the stock a "buy" rating in a research report on Thursday, June 26th. Finally, UBS Group lifted their price target on Qiagen from $48.00 to $50.00 and gave the company a "neutral" rating in a research note on Thursday, August 7th. Three investment analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company. According to MarketBeat.com, Qiagen presently has an average rating of "Hold" and a consensus target price of $49.69.

Qiagen Trading Up 1.1%

Qiagen stock traded up $0.50 during mid-day trading on Friday, hitting $47.54. 939,634 shares of the stock were exchanged, compared to its average volume of 1,350,406. The company has a quick ratio of 1.35, a current ratio of 1.61 and a debt-to-equity ratio of 0.25. Qiagen N.V. has a 12 month low of $37.63 and a 12 month high of $51.88. The firm's fifty day simple moving average is $48.65 and its two-hundred day simple moving average is $44.35. The stock has a market capitalization of $10.57 billion, a price-to-earnings ratio of 28.08, a PEG ratio of 2.48 and a beta of 0.64.

Qiagen (NYSE:QGEN - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The company reported $0.60 earnings per share for the quarter, meeting the consensus estimate of $0.60. The firm had revenue of $533.54 million for the quarter, compared to analysts' expectations of $523.97 million. Qiagen had a return on equity of 14.77% and a net margin of 18.30%.The company's revenue was up 7.7% on a year-over-year basis. During the same period in the prior year, the business posted $0.55 earnings per share. Qiagen has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. Analysts forecast that Qiagen N.V. will post 2.26 EPS for the current year.

Qiagen Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.